Work

Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw379.37

Authors: P.A. Ascierto, A. Ribas, J. Larkin, G.A. McArthur, K.D. Lewis, A. Hauschild, K.T. Flaherty, E. McKenna, Q. Zhu, Y. Mun, B. Dréno

Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Peter MacCallum Cancer Centre, University of Colorado Cancer Center, University Hospital Schleswig-Holstein, Massachusetts General Hospital, Genentech, Nantes Université

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2586449620

FWCI: 0.452

Cites:

Cited by: 4

Related to: 10